Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial
BACKGROUND Prostate cancer is highly influenced by androgens and genes. The authors investigated whether genetic polymorphisms along the androgen biosynthesis and metabolism pathways are associated with androgen concentrations or with the risk of prostate cancer or high‐grade disease from finasterid...
Gespeichert in:
| Veröffentlicht in: | Cancer 2016-08, Vol.122 (15), p.2332-2340 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2340 |
|---|---|
| container_issue | 15 |
| container_start_page | 2332 |
| container_title | Cancer |
| container_volume | 122 |
| creator | Price, Douglas K. Chau, Cindy H. Till, Cathee Goodman, Phyllis J. Leach, Robin J. Johnson‐Pais, Teresa L. Hsing, Ann W. Hoque, Ashraful Parnes, Howard L. Schenk, Jeannette M. Tangen, Catherine M. Thompson, Ian M. Reichardt, Juergen K. V. Figg, William D. |
| description | BACKGROUND
Prostate cancer is highly influenced by androgens and genes. The authors investigated whether genetic polymorphisms along the androgen biosynthesis and metabolism pathways are associated with androgen concentrations or with the risk of prostate cancer or high‐grade disease from finasteride treatment.
METHODS
A nested case‐control study from the Prostate Cancer Prevention Trial using data from men who had biopsy‐proven prostate cancer (cases) and a group of biopsy‐negative, frequency‐matched controls was conducted to investigate the association of 51 single nucleotide polymorphisms (SNPs) in 12 genes of the androgen pathway with overall (total), low‐grade, and high‐grade prostate cancer incidence and serum hormone concentrations.
RESULTS
There were significant associations of genetic polymorphisms in steroid 5α‐reductase 1 (SRD5A1) (reference SNPs: rs3736316, rs3822430, rs1560149, rs248797, and rs472402) and SRD5A2 (rs2300700) with the risk of high‐grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial; 2 SNPs were significantly associated with an increased risk (SRD5A1 rs472402 [odds ratio, 1.70; 95% confidence interval, 1.05‐2.75; Ptrend = .03] and SRD5A2 rs2300700 [odds ratio, 1.94; 95% confidence interval, 1.19‐3.18; Ptrend = .01]). Eleven SNPs in SRD5A1, SRD5A2, cytochrome P450 family 1, subfamily B, polypeptide 1 (CYP1B1), and CYP3A4 were associated with modifying the mean concentrations of serum androgen and sex hormone‐binding globulin; and 2 SNPs (SRD5A1 rs824811 and CYP1B1 rs10012; Ptrend < .05) consistently and significantly altered all androgen concentrations. Several SNPs (SRD5A1 rs3822430, SRD5A2 rs2300700, CYP3A43 rs800672, and CYP19 rs700519; Ptrend < .05) were significantly associated with both circulating hormone levels and prostate cancer risk.
CONCLUSIONS
Germline genetic variations of androgen‐related pathway genes are associated with serum androgen concentrations and the risk of prostate cancer. Further studies to examine the functional consequence of novel causal variants are warranted. Cancer 2016;122:2332–2340. © 2016 American Cancer Society.
This case‐control study from the Prostate Cancer Prevention Trial study demonstrates the significance of androgen metabolism in prostate cancer and suggests that genetic variations along the androgen pathway modify serum hormone concentrations, contributing to the risk of prostate cancer, and that subgroups of men may be more susceptible to the disease. Find |
| doi_str_mv | 10.1002/cncr.30071 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4956504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1811901717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4531-b63bdbbd67e34697e28f5727c5fbe2c8f760525b9d080fc43eccfd5012d4655f3</originalsourceid><addsrcrecordid>eNqNkV9r1jAUh4Mo7nV64weQXIrQmTRJ03ohjOI_GDrGBO9Cmp7sjaZNl_TdeL-Mn9V03abeiFfh5Dx5OCc_hJ5TckQJKV-b0cQjRoikD9CGkkYWhPLyIdoQQupCcPbtAD1J6XsuZSnYY3RQSlpx2tAN-nmcUjBOzy6MOFisxz6GCxjxALPugndpwLkEPAW_H0Kctvkm4Ws3b_EUQ5r1DNjo0UDE0aUfi-C3xITcGOd4o09v8BmknZ8TtjEMeN4CPr1TtKviNMJVfrAMcx6d9k_RI6t9gme35yH6-v7defuxOPny4VN7fFIYLhgtuop1fdf1lQTGq0ZCWVshS2mE7aA0tZUVEaXomp7UxBrOwBjbC0LLnldCWHaI3q7eadcN0K9DezVFN-i4V0E79XdndFt1Ea4Ub0QlCM-Cl7eCGC53kGY1uGTAez1C2CVFa0obQiWV_4GSinPO5GJ9taIm_1OKYO8nokQt2asle3WTfYZf_LnDPXoXdgboClw7D_t_qFT7uT1bpb8A1WS_JQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1806444374</pqid></control><display><type>article</type><title>Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial</title><source>MEDLINE</source><source>Wiley Free Archive</source><source>Wiley Online Library All Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Price, Douglas K. ; Chau, Cindy H. ; Till, Cathee ; Goodman, Phyllis J. ; Leach, Robin J. ; Johnson‐Pais, Teresa L. ; Hsing, Ann W. ; Hoque, Ashraful ; Parnes, Howard L. ; Schenk, Jeannette M. ; Tangen, Catherine M. ; Thompson, Ian M. ; Reichardt, Juergen K. V. ; Figg, William D.</creator><creatorcontrib>Price, Douglas K. ; Chau, Cindy H. ; Till, Cathee ; Goodman, Phyllis J. ; Leach, Robin J. ; Johnson‐Pais, Teresa L. ; Hsing, Ann W. ; Hoque, Ashraful ; Parnes, Howard L. ; Schenk, Jeannette M. ; Tangen, Catherine M. ; Thompson, Ian M. ; Reichardt, Juergen K. V. ; Figg, William D.</creatorcontrib><description>BACKGROUND
Prostate cancer is highly influenced by androgens and genes. The authors investigated whether genetic polymorphisms along the androgen biosynthesis and metabolism pathways are associated with androgen concentrations or with the risk of prostate cancer or high‐grade disease from finasteride treatment.
METHODS
A nested case‐control study from the Prostate Cancer Prevention Trial using data from men who had biopsy‐proven prostate cancer (cases) and a group of biopsy‐negative, frequency‐matched controls was conducted to investigate the association of 51 single nucleotide polymorphisms (SNPs) in 12 genes of the androgen pathway with overall (total), low‐grade, and high‐grade prostate cancer incidence and serum hormone concentrations.
RESULTS
There were significant associations of genetic polymorphisms in steroid 5α‐reductase 1 (SRD5A1) (reference SNPs: rs3736316, rs3822430, rs1560149, rs248797, and rs472402) and SRD5A2 (rs2300700) with the risk of high‐grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial; 2 SNPs were significantly associated with an increased risk (SRD5A1 rs472402 [odds ratio, 1.70; 95% confidence interval, 1.05‐2.75; Ptrend = .03] and SRD5A2 rs2300700 [odds ratio, 1.94; 95% confidence interval, 1.19‐3.18; Ptrend = .01]). Eleven SNPs in SRD5A1, SRD5A2, cytochrome P450 family 1, subfamily B, polypeptide 1 (CYP1B1), and CYP3A4 were associated with modifying the mean concentrations of serum androgen and sex hormone‐binding globulin; and 2 SNPs (SRD5A1 rs824811 and CYP1B1 rs10012; Ptrend < .05) consistently and significantly altered all androgen concentrations. Several SNPs (SRD5A1 rs3822430, SRD5A2 rs2300700, CYP3A43 rs800672, and CYP19 rs700519; Ptrend < .05) were significantly associated with both circulating hormone levels and prostate cancer risk.
CONCLUSIONS
Germline genetic variations of androgen‐related pathway genes are associated with serum androgen concentrations and the risk of prostate cancer. Further studies to examine the functional consequence of novel causal variants are warranted. Cancer 2016;122:2332–2340. © 2016 American Cancer Society.
This case‐control study from the Prostate Cancer Prevention Trial study demonstrates the significance of androgen metabolism in prostate cancer and suggests that genetic variations along the androgen pathway modify serum hormone concentrations, contributing to the risk of prostate cancer, and that subgroups of men may be more susceptible to the disease. Findings from this study provide further insight into the genetic etiology of the increased risk of high‐grade cancer among men who receive treatment with finasteride.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.30071</identifier><identifier>PMID: 27164191</identifier><language>eng</language><publisher>United States</publisher><subject>Alleles ; androgen ; Androgens - blood ; Androgens - metabolism ; Biomarkers ; Case-Control Studies ; Clinical Trials as Topic ; Genetic Association Studies ; Genetic Predisposition to Disease ; genetics ; Genotype ; Humans ; Male ; Metabolic Networks and Pathways - genetics ; metabolism ; Neoplasm Grading ; Odds Ratio ; polymorphism ; Polymorphism, Genetic ; Polymorphism, Single Nucleotide ; prostate cancer ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - etiology ; Prostatic Neoplasms - metabolism</subject><ispartof>Cancer, 2016-08, Vol.122 (15), p.2332-2340</ispartof><rights>2016 American Cancer Society</rights><rights>2016 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4531-b63bdbbd67e34697e28f5727c5fbe2c8f760525b9d080fc43eccfd5012d4655f3</citedby><cites>FETCH-LOGICAL-c4531-b63bdbbd67e34697e28f5727c5fbe2c8f760525b9d080fc43eccfd5012d4655f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.30071$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.30071$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27164191$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Price, Douglas K.</creatorcontrib><creatorcontrib>Chau, Cindy H.</creatorcontrib><creatorcontrib>Till, Cathee</creatorcontrib><creatorcontrib>Goodman, Phyllis J.</creatorcontrib><creatorcontrib>Leach, Robin J.</creatorcontrib><creatorcontrib>Johnson‐Pais, Teresa L.</creatorcontrib><creatorcontrib>Hsing, Ann W.</creatorcontrib><creatorcontrib>Hoque, Ashraful</creatorcontrib><creatorcontrib>Parnes, Howard L.</creatorcontrib><creatorcontrib>Schenk, Jeannette M.</creatorcontrib><creatorcontrib>Tangen, Catherine M.</creatorcontrib><creatorcontrib>Thompson, Ian M.</creatorcontrib><creatorcontrib>Reichardt, Juergen K. V.</creatorcontrib><creatorcontrib>Figg, William D.</creatorcontrib><title>Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
Prostate cancer is highly influenced by androgens and genes. The authors investigated whether genetic polymorphisms along the androgen biosynthesis and metabolism pathways are associated with androgen concentrations or with the risk of prostate cancer or high‐grade disease from finasteride treatment.
METHODS
A nested case‐control study from the Prostate Cancer Prevention Trial using data from men who had biopsy‐proven prostate cancer (cases) and a group of biopsy‐negative, frequency‐matched controls was conducted to investigate the association of 51 single nucleotide polymorphisms (SNPs) in 12 genes of the androgen pathway with overall (total), low‐grade, and high‐grade prostate cancer incidence and serum hormone concentrations.
RESULTS
There were significant associations of genetic polymorphisms in steroid 5α‐reductase 1 (SRD5A1) (reference SNPs: rs3736316, rs3822430, rs1560149, rs248797, and rs472402) and SRD5A2 (rs2300700) with the risk of high‐grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial; 2 SNPs were significantly associated with an increased risk (SRD5A1 rs472402 [odds ratio, 1.70; 95% confidence interval, 1.05‐2.75; Ptrend = .03] and SRD5A2 rs2300700 [odds ratio, 1.94; 95% confidence interval, 1.19‐3.18; Ptrend = .01]). Eleven SNPs in SRD5A1, SRD5A2, cytochrome P450 family 1, subfamily B, polypeptide 1 (CYP1B1), and CYP3A4 were associated with modifying the mean concentrations of serum androgen and sex hormone‐binding globulin; and 2 SNPs (SRD5A1 rs824811 and CYP1B1 rs10012; Ptrend < .05) consistently and significantly altered all androgen concentrations. Several SNPs (SRD5A1 rs3822430, SRD5A2 rs2300700, CYP3A43 rs800672, and CYP19 rs700519; Ptrend < .05) were significantly associated with both circulating hormone levels and prostate cancer risk.
CONCLUSIONS
Germline genetic variations of androgen‐related pathway genes are associated with serum androgen concentrations and the risk of prostate cancer. Further studies to examine the functional consequence of novel causal variants are warranted. Cancer 2016;122:2332–2340. © 2016 American Cancer Society.
This case‐control study from the Prostate Cancer Prevention Trial study demonstrates the significance of androgen metabolism in prostate cancer and suggests that genetic variations along the androgen pathway modify serum hormone concentrations, contributing to the risk of prostate cancer, and that subgroups of men may be more susceptible to the disease. Findings from this study provide further insight into the genetic etiology of the increased risk of high‐grade cancer among men who receive treatment with finasteride.</description><subject>Alleles</subject><subject>androgen</subject><subject>Androgens - blood</subject><subject>Androgens - metabolism</subject><subject>Biomarkers</subject><subject>Case-Control Studies</subject><subject>Clinical Trials as Topic</subject><subject>Genetic Association Studies</subject><subject>Genetic Predisposition to Disease</subject><subject>genetics</subject><subject>Genotype</subject><subject>Humans</subject><subject>Male</subject><subject>Metabolic Networks and Pathways - genetics</subject><subject>metabolism</subject><subject>Neoplasm Grading</subject><subject>Odds Ratio</subject><subject>polymorphism</subject><subject>Polymorphism, Genetic</subject><subject>Polymorphism, Single Nucleotide</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - etiology</subject><subject>Prostatic Neoplasms - metabolism</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV9r1jAUh4Mo7nV64weQXIrQmTRJ03ohjOI_GDrGBO9Cmp7sjaZNl_TdeL-Mn9V03abeiFfh5Dx5OCc_hJ5TckQJKV-b0cQjRoikD9CGkkYWhPLyIdoQQupCcPbtAD1J6XsuZSnYY3RQSlpx2tAN-nmcUjBOzy6MOFisxz6GCxjxALPugndpwLkEPAW_H0Kctvkm4Ws3b_EUQ5r1DNjo0UDE0aUfi-C3xITcGOd4o09v8BmknZ8TtjEMeN4CPr1TtKviNMJVfrAMcx6d9k_RI6t9gme35yH6-v7defuxOPny4VN7fFIYLhgtuop1fdf1lQTGq0ZCWVshS2mE7aA0tZUVEaXomp7UxBrOwBjbC0LLnldCWHaI3q7eadcN0K9DezVFN-i4V0E79XdndFt1Ea4Ub0QlCM-Cl7eCGC53kGY1uGTAez1C2CVFa0obQiWV_4GSinPO5GJ9taIm_1OKYO8nokQt2asle3WTfYZf_LnDPXoXdgboClw7D_t_qFT7uT1bpb8A1WS_JQ</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Price, Douglas K.</creator><creator>Chau, Cindy H.</creator><creator>Till, Cathee</creator><creator>Goodman, Phyllis J.</creator><creator>Leach, Robin J.</creator><creator>Johnson‐Pais, Teresa L.</creator><creator>Hsing, Ann W.</creator><creator>Hoque, Ashraful</creator><creator>Parnes, Howard L.</creator><creator>Schenk, Jeannette M.</creator><creator>Tangen, Catherine M.</creator><creator>Thompson, Ian M.</creator><creator>Reichardt, Juergen K. V.</creator><creator>Figg, William D.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TO</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20160801</creationdate><title>Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial</title><author>Price, Douglas K. ; Chau, Cindy H. ; Till, Cathee ; Goodman, Phyllis J. ; Leach, Robin J. ; Johnson‐Pais, Teresa L. ; Hsing, Ann W. ; Hoque, Ashraful ; Parnes, Howard L. ; Schenk, Jeannette M. ; Tangen, Catherine M. ; Thompson, Ian M. ; Reichardt, Juergen K. V. ; Figg, William D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4531-b63bdbbd67e34697e28f5727c5fbe2c8f760525b9d080fc43eccfd5012d4655f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Alleles</topic><topic>androgen</topic><topic>Androgens - blood</topic><topic>Androgens - metabolism</topic><topic>Biomarkers</topic><topic>Case-Control Studies</topic><topic>Clinical Trials as Topic</topic><topic>Genetic Association Studies</topic><topic>Genetic Predisposition to Disease</topic><topic>genetics</topic><topic>Genotype</topic><topic>Humans</topic><topic>Male</topic><topic>Metabolic Networks and Pathways - genetics</topic><topic>metabolism</topic><topic>Neoplasm Grading</topic><topic>Odds Ratio</topic><topic>polymorphism</topic><topic>Polymorphism, Genetic</topic><topic>Polymorphism, Single Nucleotide</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - etiology</topic><topic>Prostatic Neoplasms - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Price, Douglas K.</creatorcontrib><creatorcontrib>Chau, Cindy H.</creatorcontrib><creatorcontrib>Till, Cathee</creatorcontrib><creatorcontrib>Goodman, Phyllis J.</creatorcontrib><creatorcontrib>Leach, Robin J.</creatorcontrib><creatorcontrib>Johnson‐Pais, Teresa L.</creatorcontrib><creatorcontrib>Hsing, Ann W.</creatorcontrib><creatorcontrib>Hoque, Ashraful</creatorcontrib><creatorcontrib>Parnes, Howard L.</creatorcontrib><creatorcontrib>Schenk, Jeannette M.</creatorcontrib><creatorcontrib>Tangen, Catherine M.</creatorcontrib><creatorcontrib>Thompson, Ian M.</creatorcontrib><creatorcontrib>Reichardt, Juergen K. V.</creatorcontrib><creatorcontrib>Figg, William D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Price, Douglas K.</au><au>Chau, Cindy H.</au><au>Till, Cathee</au><au>Goodman, Phyllis J.</au><au>Leach, Robin J.</au><au>Johnson‐Pais, Teresa L.</au><au>Hsing, Ann W.</au><au>Hoque, Ashraful</au><au>Parnes, Howard L.</au><au>Schenk, Jeannette M.</au><au>Tangen, Catherine M.</au><au>Thompson, Ian M.</au><au>Reichardt, Juergen K. V.</au><au>Figg, William D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>122</volume><issue>15</issue><spage>2332</spage><epage>2340</epage><pages>2332-2340</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>BACKGROUND
Prostate cancer is highly influenced by androgens and genes. The authors investigated whether genetic polymorphisms along the androgen biosynthesis and metabolism pathways are associated with androgen concentrations or with the risk of prostate cancer or high‐grade disease from finasteride treatment.
METHODS
A nested case‐control study from the Prostate Cancer Prevention Trial using data from men who had biopsy‐proven prostate cancer (cases) and a group of biopsy‐negative, frequency‐matched controls was conducted to investigate the association of 51 single nucleotide polymorphisms (SNPs) in 12 genes of the androgen pathway with overall (total), low‐grade, and high‐grade prostate cancer incidence and serum hormone concentrations.
RESULTS
There were significant associations of genetic polymorphisms in steroid 5α‐reductase 1 (SRD5A1) (reference SNPs: rs3736316, rs3822430, rs1560149, rs248797, and rs472402) and SRD5A2 (rs2300700) with the risk of high‐grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial; 2 SNPs were significantly associated with an increased risk (SRD5A1 rs472402 [odds ratio, 1.70; 95% confidence interval, 1.05‐2.75; Ptrend = .03] and SRD5A2 rs2300700 [odds ratio, 1.94; 95% confidence interval, 1.19‐3.18; Ptrend = .01]). Eleven SNPs in SRD5A1, SRD5A2, cytochrome P450 family 1, subfamily B, polypeptide 1 (CYP1B1), and CYP3A4 were associated with modifying the mean concentrations of serum androgen and sex hormone‐binding globulin; and 2 SNPs (SRD5A1 rs824811 and CYP1B1 rs10012; Ptrend < .05) consistently and significantly altered all androgen concentrations. Several SNPs (SRD5A1 rs3822430, SRD5A2 rs2300700, CYP3A43 rs800672, and CYP19 rs700519; Ptrend < .05) were significantly associated with both circulating hormone levels and prostate cancer risk.
CONCLUSIONS
Germline genetic variations of androgen‐related pathway genes are associated with serum androgen concentrations and the risk of prostate cancer. Further studies to examine the functional consequence of novel causal variants are warranted. Cancer 2016;122:2332–2340. © 2016 American Cancer Society.
This case‐control study from the Prostate Cancer Prevention Trial study demonstrates the significance of androgen metabolism in prostate cancer and suggests that genetic variations along the androgen pathway modify serum hormone concentrations, contributing to the risk of prostate cancer, and that subgroups of men may be more susceptible to the disease. Findings from this study provide further insight into the genetic etiology of the increased risk of high‐grade cancer among men who receive treatment with finasteride.</abstract><cop>United States</cop><pmid>27164191</pmid><doi>10.1002/cncr.30071</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2016-08, Vol.122 (15), p.2332-2340 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4956504 |
| source | MEDLINE; Wiley Free Archive; Wiley Online Library All Journals; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Alleles androgen Androgens - blood Androgens - metabolism Biomarkers Case-Control Studies Clinical Trials as Topic Genetic Association Studies Genetic Predisposition to Disease genetics Genotype Humans Male Metabolic Networks and Pathways - genetics metabolism Neoplasm Grading Odds Ratio polymorphism Polymorphism, Genetic Polymorphism, Single Nucleotide prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - etiology Prostatic Neoplasms - metabolism |
| title | Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A04%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20androgen%20metabolism%20gene%20polymorphisms%20with%20prostate%20cancer%20risk%20and%20androgen%20concentrations:%20Results%20from%20the%20Prostate%20Cancer%20Prevention%20Trial&rft.jtitle=Cancer&rft.au=Price,%20Douglas%20K.&rft.date=2016-08-01&rft.volume=122&rft.issue=15&rft.spage=2332&rft.epage=2340&rft.pages=2332-2340&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.30071&rft_dat=%3Cproquest_pubme%3E1811901717%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1806444374&rft_id=info:pmid/27164191&rfr_iscdi=true |